Cardiac Rhythm And PFA Drive Medtronic Q3 Beat; MiniMed Separation On Track
Medtronic said its MiniMed Fit patch pump development remains on schedule, with plans to submit the device to the US Food and Drug Administration by the fall.
Medtech Insight - February 18, 2026

Biopharma Deal Making In 2026: Confidence Returns, But On New Terms
Executives from Novo Nordisk, Ipsen, Astellas, Acadia and Flagship Pioneering agree: the dealmaking environment is improving but the calculus has changed. Flexible structures, sharper therapeutic focus, and the long shadow of patent cliffs and pricing policy are reshaping how partnerships get done.
In Vivo - February 18, 2026

Medtronic’s Hugo Used In First US Case As Company Targets Expansion Beyond Urology
While surgical technologies is a roughly $6bn Medtronic business with “various moving parts,” Hugo is not yet large enough to materially shift surgical performance, it is growing at a strong pace, CEO Geoff Martha said.
Medtech Insight - February 18, 2026

Big Promises, Long Timelines – Trump’s US Pharma Investment Push
While investment promises appear to be in billions of dollars, industry experts remain skeptical.
Scrip - February 18, 2026

Enzymatica’s New Boss Bullish On International Expansion
Sana Alajmovic is seeing strong interest from potential partners to launch virus-blocking mouth spray ColdZyme in new markets around the world.
HBW Insight - February 18, 2026

England Unlocks £560m Savings With Generic Dapagliflozin Policy
SGLT-2 inhibitors should be used to treat patients with type 2 diabetes much earlier in their treatment, the English health technology assessment institute said, adding that using generic dapagliflozin would save the National Health Service £560m.
Generics Bulletin - February 18, 2026

Lilly Leaps Into IL-6 Space With CSL Clazakizumab Pact
Deal Snapshot: Eli Lilly is the latest big pharma player to explore the potential of interleukin-6 in an multi-million dollar agreement with troubled Australian firm CSL.
Scrip - February 18, 2026

France’s OTC Market: Volumes Down In 2025 – But Self?Care Still the Answer
Increased sales of dietary supplements softened France’s 2025 volume decline, which was driven by a mild respiratory season. French self-care industry association NèreS calls for expanded pharmacist authority and broader non?prescription access to strengthen the country’s first line of care.
HBW Insight - February 18, 2026

Deals In Depth: January 2026
Nine $1bn+ alliances were penned in January, and three exceeded $2bn. In the top alliance by deal value, RemeGen granted AbbVie exclusive global rights (excluding Greater China) to develop, manufacture, and commercialize RC148 for non-small cell lung cancer and other solid tumors.
In Vivo - February 18, 2026

10 Clinical Trials To Look Out For In 2026
2026 has already seen some interesting late-stage trial readouts, from Sanofi’s anti-OX40L antibody, amlitelimab, in atopic dermatitis to Vertex’s APRIL/BAFF inhibitor, povetacicept, in IgA nephropathy. Here Scrip surveys of some of the more interesting Phase III clinical trials still to come.
Scrip - February 18, 2026

Bayer Seeks ‘Greatest Possible Closure’ Of Roundup Claims With Over $7bn Settlement
The settlement could give Bayer long?sought clarity on its legal exposure while reopening questions about the company’s future structure and strategy.
Scrip - February 18, 2026

Execs On The Move: January 2026
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - February 18, 2026

Biocon To Explore Further Possibilities For Fully Acquired Humira Biosimilar
Biocon Biologics hinted about exploring the development of a higher concentration adalimumab biosimilar, now that it has full rights to the Hulio franchise.
Generics Bulletin - February 18, 2026

‘This Requires More Than Isolated Policy Interventions’ – Centrient Urges EU To Bolster Supply Chain
Centrient has urged the EU to strengthen its supply chain resilience, including incentivizing local manufacturing through revised procurement practices, after India took action to protect its antibiotics market from an increasing Chinese monopoly.
Generics Bulletin - February 18, 2026

Telemonitoring And Medtech Data ‘Should Be Central To Germany’s 2030 Digital Strategy’
Germany’s updated digital healthcare “manifesto” document reflects the need to dovetail with EU’s EHDS and factor in advances in AI, and provide for a new system of primary care. The medtech industry calls for faster assessments of AI-enabled technology and better access to telemonitoring tools.
Medtech Insight - February 18, 2026

Italy’s OTC Market: Long-Term Volume Growth Requires More Rx-to-OTC Switches
While Italy’s non-prescription medicines market has stabilized following the volatility of the coronavirus pandemic, unlocking sustainable volume growth will require further Rx-to-OTC switches, argues the country's consumer health industry association, Assosalute.
HBW Insight - February 18, 2026

Leo Roars Into Profit As Anzupgo Lifts Off
With the ongoing launch of the chronic hand eczema therapy, and the addition of Spevigo, the Danish group has entered 2026 with strong momentum, its CEO Christophe Bourdon tells Scrip.
Scrip - February 18, 2026

US FDA Proposing White House-Aligned Policies For User Fee Agreements
User fee program changes traditionally are technical and FDA-specific, but the Trump Administration appears to also want policies advocating its “America First” agenda included.
HBW Insight - February 18, 2026

Senate HELP Committee Recommends Tightening Food Safety Oversight Without Cutting Self-GRAS
GRAS observations included a report on modernizing FDA published as consumer health industry and food safety advocacy and research groups meet with FDA and OMB officials to offer recommendations for and against a proposed rule agency intends to publish on eliminating self-affirmed GRAS option.
HBW Insight - February 18, 2026

Chinese ADC, Cell/Gene Therapy Biotechs Ride Funding Spree
2026 has already seen several major new funding rounds for Chinese biopharma ventures, including a $70m financing for CAR-T specialist Oricell and a $40m Angel round for ADC specialist Tosun.
Scrip - February 18, 2026